These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19214513)

  • 1. [ErbB2 diagnostics in breast cancer--an update].
    Rüschoff J; Nagelmeier I; Hofmann M; Henkel T; Stoss O
    Pathologe; 2009 Mar; 30(2):147-55. PubMed ID: 19214513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
    Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
    Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.
    Mostafa NA; Eissa SS; Belal DM; Shoman SH
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):41-6. PubMed ID: 22099935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FISH and HER2/
    Patil Okaly GV; Panwar D; Lingappa KB; Kumari P; Anand A; Kumar P; Chikkalingaiah MH; Kumar RV
    Indian J Cancer; 2019; 56(2):119-123. PubMed ID: 31062729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
    Hammock L; Lewis M; Phillips C; Cohen C
    Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.